- Home
- GGZ vs SPRO Comparison
GGZ vs SPRO Comparison
Compare GGZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGZ | SPRO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.3M | 135.5M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GGZ | SPRO |
|---|---|---|
| Price | $15.74 | $2.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.3K | ★ 730.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $12.45 | $1.80 |
| 52 Week High | $16.80 | $3.09 |
Technical Indicators
Market Signals| Indicator | GGZ | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 51.01 | 55.60 |
| Support Level | $15.33 | $2.18 |
| Resistance Level | $16.32 | $2.90 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 81.43 | 59.86 |
Price Performance
Historical ComparisonAbout GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.